Literature DB >> 28974999

Malignant Posterior Reversible Encephalopathy Syndrome-An Exacting Challenge for Neurocritical Care Physicians.

Shahvaiz Magsi1, Atif Zafar2.   

Abstract

We report a case of malignant posterior reversible encephalopathy syndrome (PRES) in a 62-year-old Caucasian female with a complex medical history and comorbidities admitted for bowel resection and lysis of iatrogenic bowel adhesions and enterocutaneous fistulas. Postoperatively, the patient developed sudden bilateral visual loss with no other neurologic deficits. Computed tomography scan showed very severe PRES-like changes, confirmed on magnetic resonance imaging (MRI). Systolic blood pressure remained around 170 mm HG. The patient was obtunded and remained unresponsive after MRI, with minimal response and a deteriorating clinical condition. The patient was given hyperosmolar therapy with a mannitol bolus. She recovered well with near resolution of imaging findings.

Entities:  

Keywords:  cerebral edema; hyperosmolar therapy; malignant PRES; parenchymal hemorrhage; posterior reversible encephalopathy syndrome

Year:  2017        PMID: 28974999      PMCID: PMC5613866          DOI: 10.1177/1941874416688989

Source DB:  PubMed          Journal:  Neurohospitalist        ISSN: 1941-8744


  18 in total

Review 1.  Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed.

Authors:  V L Stott; M A Hurrell; T J Anderson
Journal:  Intern Med J       Date:  2005-02       Impact factor: 2.048

2.  A unique case of rituximab-related posterior reversible encephalopathy syndrome in a heart transplant recipient with posttransplant lymphoproliferative disorder.

Authors:  A Jaiswal; I Sabnani; D A Baran; M J Zucker
Journal:  Am J Transplant       Date:  2015-02-03       Impact factor: 8.086

3.  A case of posterior reversible encephalopathy syndrome after emergence from anesthesia.

Authors:  Satoki Inoue; Masahiko Kawaguchi; Hitoshi Furuya
Journal:  J Anesth       Date:  2011-10-20       Impact factor: 2.078

4.  Atypical posterior reversible encephalopathy syndrome associated with chemotherapy with Bevacizumab, Gemcitabine and Cisplatin.

Authors:  R Dersch; O Stich; K Goller; S Meckel; F Dechent; S Doostkam; C Weiller; J Bardutzky
Journal:  J Neurol       Date:  2013-02-21       Impact factor: 4.849

Review 5.  Therapy and differential diagnosis of posterior reversible encephalopathy syndrome (PRES) during pregnancy and postpartum.

Authors:  Mauro Cozzolino; Claudia Bianchi; Giulia Mariani; Laura Marchi; Massimiliano Fambrini; Federico Mecacci
Journal:  Arch Gynecol Obstet       Date:  2015-06-30       Impact factor: 2.344

6.  Posterior reversible encephalopathy syndrome in a hypertensive patient with renal failure.

Authors:  T Aatif; M R El Farouki; M Benyahia
Journal:  Saudi J Kidney Dis Transpl       Date:  2016-03

7.  Posterior leukoencephalopathy following intrathecal chemotherapy with MRA-documented vasospasm.

Authors:  R D Henderson; T Rajah; A J Nicol; S J Read
Journal:  Neurology       Date:  2003-01-28       Impact factor: 9.910

8.  Tacrolimus associated posterior reversible encephalopathy syndrome - a case series and review.

Authors:  Susmitha Apuri; Kristin Carlin; Edward Bass; Phuong Thuy Nguyen; John N Greene
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-02-18       Impact factor: 2.576

9.  Polyarteritis nodosa complicated by posterior reversible encephalopathy syndrome: a case report.

Authors:  Mitrakrishnan Rayno Navinan; Chandrika Jayakanthi Subasinghe; Thambyaiah Kandeepan; Aruna Kulatunga
Journal:  BMC Res Notes       Date:  2014-02-14

10.  Post-streptococcal glomerulonephritis leading to posterior reversible encephalopathy syndrome: a case report.

Authors:  Madura Adikari; Dilani Priyangika; Indika Marasingha; Sharmila Thamotheram; Gayani Premawansa
Journal:  BMC Res Notes       Date:  2014-09-13
View more
  1 in total

1.  Clinical and MRI Features of Posterior Reversible Encephalopathy Syndrome With Atypical Regions: A Descriptive Study With a Large Sample Size.

Authors:  Kunhua Li; Yang Yang; Dajing Guo; Dong Sun; Chuanming Li
Journal:  Front Neurol       Date:  2020-03-24       Impact factor: 4.003

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.